比美吉珠单抗治疗中重度斑块状银屑病两年中期结果
BE RADIANT 3b期随机对照试验开放标签延长期显示,第48周比美吉珠单抗组完全皮损清除(PASI 100)率高于司库奇尤单抗组(74.8% vs 52.8%)。持续比美吉珠单抗治疗者第96周PASI 100应答维持(70.8%),由司库奇尤单抗转换者第96周应答率升高至76.6%。安全性特征与已知一致。
要点
- 第48周PASI 100:比美吉珠单抗组74.8%,司库奇尤单抗组52.8%。
- 持续比美吉珠单抗治疗者第96周PASI 100应答率为70.8%。
- 由司库奇尤单抗转换至比美吉珠单抗者第96周PASI 100应答率为76.6%。
核心结论
- 比美吉珠单抗治疗48周获得的高PASI 100应答维持至第96周。
- 由司库奇尤单抗转换至比美吉珠单抗的患者至第96周获得相似应答。
研究设计与样本
- BE RADIANT 3b期随机对照试验,包括48周双盲期和开放标签延长期(OLE)。
- 双盲期内患者接受比美吉珠单抗320 mg每4周或每8周,或司库奇尤单抗300 mg(第4周前每周,之后每4周)。
- 自第48周起,所有患者在OLE中接受比美吉珠单抗治疗。
主要发现
- 第48周达到完全皮损清除(PASI 100;改良无应答者填补)的患者比例:比美吉珠单抗组74.8% vs 司库奇尤单抗组52.8%。
- 持续比美吉珠单抗治疗患者第96周PASI 100应答率为70.8%。
- 由司库奇尤单抗转换至比美吉珠单抗的患者第96周PASI 100应答率升高至76.6%。
- 最常见不良事件为鼻咽炎、口腔念珠菌病和尿路感染。
- 安全性数据与比美吉珠单抗已知安全性特征一致。
临床怎么用
- 原文未据此给出推荐。
局限性
- 种族多样性有限。
- 与COVID-19大流行重叠。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bimekizumab is a monoclonal IgG1 antibody that inhibits interleukin-17A/F. Bimekizumab is more efficacious than secukinumab over 1 year in the treatment of psoriasis. OBJECTIVE: Evaluate the safety and efficacy of bimekizumab through 2 years in patients with moderate to severe plaque psoriasis. METHODS: The BE RADIANT phase 3b randomized controlled trial consisted of a 48-week double-blinded period, where patients received bimekizumab (320 mg every 4 or 8 weeks) or secukinumab (300 mg weekly to Week 4, then every 4 weeks), and an open-label extension (OLE). From Week 48, all patients received bimekizumab in the OLE. RESULTS: At Week 48, more patients achieved complete skin clearance (PASI 100; modified non-responder imputation) with bimekizumab than secukinumab (74.8% vs 52.8%). PASI 100 responses were maintained to Week 96 in continuous bimekizumab patients (70.8%); patients who switched from secukinumab to bimekizumab had increased rates at Week 96 (76.6%). The most common adverse events were: nasopharyngitis, oral candidiasis, and urinary tract infection. Safety data were consistent with the known safety profile of bimekizumab. LIMITATIONS: Limited racial diversity; overlap with the COVID-19 pandemic. CONCLUSIONS: High PASI 100 responses achieved with bimekizumab over 48 weeks were sustained through Week 96; secukinumab patients who switched to bimekizumab achieved similar responses by Week 96.
引用
- Strober B, Paul C, Blauvelt A, et al. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. J Am Acad Dermatol. 2023. PMID: 37182701. doi:10.1016/j.jaad.2023.04.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。